Navigation Links
PAREXEL International Updates Financial Guidance in Conjunction With the Acquisition of ClinPhone Plc and Other Factors
Date:9/8/2008

actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business, including ClinPhone; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Annual Report on Form 10-K for the Fiscal Year ended June 30, 2008 as filed with the SEC on August 28, 2008, which "Risk Factors" discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company's estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward- looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press
'/>"/>
SOURCE PAREXEL International Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. PAREXEL International To Present at Thomas Weisel Partners Healthcare Conference
2. PAREXEL Data Indicate U.S. Marketing Applications for New Molecular Entities Bounce Back
3. PAREXEL Closes the Acquisition of ClinPhone
4. PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results
5. PAREXEL Promotes Dr. Mark A. Goldberg to Chief Operating Officer
6. PAREXEL Announces Date of Fourth Quarter and Fiscal Year 2008 Earnings Release and Conference Call
7. PAREXEL International Updates Earnings Guidance in Conjunction with Its Investor Day
8. PAREXEL Expands Global Clinical Logistics Capabilities
9. Parexel Invites Public to Listen to Live Webcast of Its Investor Day June 25, 2008
10. PAREXEL Enhances Early Phase Clinical Development Offering for Central Nervous System Studies
11. PAREXEL Experts to Address Key Industry Topics at the Drug Information Association 44th Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Wash. , Dec. 24, 2014   BioLife ... leading developer, manufacturer and marketer of proprietary clinical grade ... media and precision thermal shipping products for ... that it will hold its 2015 Annual Meeting of ... Because the expected date for the Annual Meeting ...
(Date:12/24/2014)... St. Louis, Missouri (PRWEB) December 23, 2014 ... and targeting Swiss biotechnology company, Syngenta, are in the ... for pretrial proceedings. The consolidated case is In Re: ... in the U.S. District Court for the District of ... litigation (MDL) has been handed over to U.S. District ...
(Date:12/24/2014)... 2014 SoundConnect’s ... to introduce cutting edge communication technology, provide ... of platform upgrades. This webinar series demonstrates ... in their quest to leverage web conferencing’s ... to SoundConnect’s Marketing Manager, Seanna Baumgartner, “Our ...
(Date:12/24/2014)... Island, New York (PRWEB) December 23, 2014 ... and the Long Island Affiliate of ITRA Global, the national ... slow but steady recovery. This is evidenced by the ... the strong stock market. Low energy costs have held ... The only negative is the housing market remaining soft. ...
Breaking Biology Technology:BioLife Solutions Sets Date for Annual Meeting of Stockholders 2Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3
... advanced energy research , , MONTREAL, July 7 ... technology company, today announced that it will jointly form ... Edmonton and the Alberta Energy Research Institute (AERI). , ... demonstration of novel catalytic conversion processes to produce advanced ...
... following letter is being released by CEL-SCI Corporation (NYSE Amex: ... , , Recently we have been hearing a great deal about the ... this is no big deal since it does not seem that serious and, ... both counts! In this letter I will show you where in the ...
... REDWOOD CITY, Calif., July 7 OncoMed Pharmaceuticals, Inc., ... cancer stem cells, today announced the appointment of Sunil ... Development. In this new position, Mr. Patel will ... directly to Paul Hastings, OncoMed,s President and Chief Executive ...
Cached Biology Technology:Enerkem Announces World-Class Advanced Energy Research Center in Edmonton, Alberta, Canada 2Enerkem Announces World-Class Advanced Energy Research Center in Edmonton, Alberta, Canada 3CEL-SCI Corporation Releases Letter to Shareholders 2CEL-SCI Corporation Releases Letter to Shareholders 3CEL-SCI Corporation Releases Letter to Shareholders 4CEL-SCI Corporation Releases Letter to Shareholders 5CEL-SCI Corporation Releases Letter to Shareholders 6CEL-SCI Corporation Releases Letter to Shareholders 7OncoMed Pharmaceuticals Appoints Sunil Patel Senior Vice President, Corporate Development 2
(Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... addition of the "Global Facial Recognition Market ... http://photos.prnewswire.com/prnh/20130307/600769 Facial ... of individuals. Facial recognition system measures the overall ... jaw edges, mouth, and the distance between eyes. ...
(Date:12/11/2014)... , Dec. 09, 2014 Research and ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has ... in India 2015-2019" report to their offering. ... this market is the adoption of multimodal biometric ... characteristic of an individual for verification and identification ...
(Date:12/11/2014)... , Dec. 10, 2014  Data Sciences ... monitoring, has released a new series of digital ... preclinical toxicology researchers. M series, part of the ... collect the best possible physiologic data when incorporating ... Adding functional endpoints to toxicology studies has evolved ...
Breaking Biology News(10 mins):Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2
... October 31, 2012 Scientists at The Scripps ... of an important set of enzymes. The new inhibitors, ... used to study the functions of enzymes known as ... regulate. Early tests in mouse macrophages suggest that DAGL-inhibiting ...
... German . , In male songbirds of the ... spring, which leads to an increase in song activity during ... evidence so far about such a clear relationship between hormonal ... degree of seasonal changes of the environment. Researchers of the ...
... identified a molecular ,flag, in women with breast cancer who ... drug tamoxifen. Tamoxifen used alongside traditional chemotherapy and ... breast cancers, is required by the tumour to grow; it ... to one third. However, about one third of patients ...
Cached Biology News:New inhibitors of elusive enzymes promise to be valuable scientific tools 2New inhibitors of elusive enzymes promise to be valuable scientific tools 3Testosterone regulates solo song of tropical birds 2Scientists unravel resistance to breast cancer treatment 2
... ultimate in utility and flexibility press-to-seal silicone ... needs of the researcher. They are available ... as sheet material that can be easily ... are autoclavable and non-cytotoxic and can be ...
Argon Calibration Source...
SHEEP ANTI ESCHERICHIA COLI...
Recombinant Rat Leptin, CF...
Biology Products: